Division of Hematology/Oncology


Gene Modified T Cell Therapy for CLL

In a cancer treatment breakthrough 20 years in the making, researchers from Penn's Abramson Cancer Center and Perelman School of Medicine demonstrated sustained remissions of up to a year among a small group of patients with advanced chronic lymphocytic leukemia (CLL) treated with genetically engineered versions of their own T cells.

The Car T Cell Trial is a clinical trial that involves removing the patientsí cells and modifying them in Penn's vaccine production facility in Philadelphia. Those cells are then infused the back into the patients following chemotherapy, providing a tumor-attack roadmap for the treatment of other cancers including those of the lung and ovaries and myeloma and melanoma.

Learn more about this groundbreaking cancer research study